Valeria Riccieri

List of Publications by Year
in descending order

215 papers	13,200 citations	31902 53 h-index	24179 110 g-index
224 all docs	224 docs citations	224 times ranked	11217 citing authors

#	Article	IF	Citations
1	Neutrophils Activate Plasmacytoid Dendritic Cells by Releasing Self-DNAâ€“Peptide Complexes in Systemic Lupus Erythematosus. Science Translational Medicine, 2011, 3, 73ra19.	5.8	1,080
2	Nintedanib for Systemic Sclerosisâ€“Associated Interstitial Lung Disease. New England Journal of Medicine, 2019, 380, 2518-2528.	13.9	1,025
3	Causes and risk factors for death in systemic sclerosis: a study from the EULAR Scleroderma Trials and Research (EUSTAR) database. Annals of the Rheumatic Diseases, 2010, 69, 1809-1815.	0.5	1,017
4	Update of EULAR recommendations for the treatment of systemic sclerosis. Annals of the Rheumatic Diseases, 2017, 76, 1327-1339.	0.5	794
5	Clinical risk assessment of organ manifestations in systemic sclerosis: a report from the EULAR Scleroderma Trials And Research group database. Annals of the Rheumatic Diseases, 2007, 66, 754-763.	0.5	739
6	EULAR recommendations for the treatment of systemic sclerosis: a report from the EULAR Scleroderma Trials and Research group (EUSTAR). Annals of the Rheumatic Diseases, 2009, 68, 620-628.	0.5	559
7	The antimicrobial peptide LL37 is a T-cell autoantigen in psoriasis. Nature Communications, 2014, 5, 5621.	5.8	427
8	Mapping and predicting mortality from systemic sclerosis. Annals of the Rheumatic Diseases, 2017, 76, 1897-1905.	0.5	410
9	Preliminary criteria for the very early diagnosis of systemic sclerosis: results of a Delphi Consensus Study from EULAR Scleroderma Trials and Research Group. Annals of the Rheumatic Diseases, 2011, 70, 476-481.	0.5	330
10	Standardisation of nailfold capillaroscopy for the assessment of patients with Raynaud's phenomenon and systemic sclerosis. Autoimmunity Reviews, 2020, 19, 102458.	2.5	231
11	Prevalence and factors associated with left ventricular dysfunction in the EULAR Scleroderma Trial and Research group (EUSTAR) database of patients with systemic sclerosis. Annals of the Rheumatic Diseases, 2010, 69, 218-221.	0.5	214
12	Genome-Wide Scan Identifies TNIP1, PSORS1C1, and RHOB as Novel Risk Loci for Systemic Sclerosis. PLoS Genetics, 2011, 7, e1002091.	1.5	205
13	Preliminary analysis of the Very Early Diagnosis of Systemic Sclerosis (VEDOSS) EUSTAR multicentre study: evidence for puffy fingers as a pivotal sign for suspicion of systemic sclerosis. Annals of the Rheumatic Diseases, 2014, 73, 2087-2093.	0.5	168
14	Outcomes of patients with systemic sclerosis-associated polyarthritis and myopathy treated with tocilizumab or abatacept: a EUSTAR observational study. Annals of the Rheumatic Diseases, 2013, 72, 1217-1220.	0.5	160
15	Incidences and Risk Factors of Organ Manifestations in the Early Course of Systemic Sclerosis: A Longitudinal EUSTAR Study. PLoS ONE, 2016, 11, e0163894.	1.1	158
16	Outcomes of patients with systemic sclerosis treated with rituximab in contemporary practice: a prospective cohort study. Annals of the Rheumatic Diseases, 2019, 78, 979-987.	0.5	142
17	Nailfold Capillaroscopy for Prediction of Novel Future Severe Organ Involvement in Systemic Sclerosis. Journal of Rheumatology, 2013, 40, 2023-2028.	1.0	137
18	Characterization and Recruitment of Plasmacytoid Dendritic Cells in Synovial Fluid and Tissue of Patients with Chronic Inflammatory Arthritis. Journal of Immunology, 2004, 173, 2815-2824.	0.4	135

#	Article	IF	Citations
19	Brief Report: Successful pregnancies but a higher risk of preterm births in patients with systemic sclerosis: An Italian multicenter study. Arthritis and Rheumatism, 2012, 64, 1970-1977.	6.7	134
20	â€œTo Be or Not To Be,â€•Ten Years After: Evidence for Mixed Connective Tissue Disease as a Distinct Entity. Seminars in Arthritis and Rheumatism, 2012, 41, 589-598.	1.6	126
21	Nailfold Videocapillaroscopic Features and Other Clinical Risk Factors for Digital Ulcers in Systemic Sclerosis: A Multicenter, Prospective Cohort Study. Arthritis and Rheumatology, 2016, 68, 2527-2539.	2.9	122
22	An EULAR study group pilot study on reliability of simple capillaroscopic definitions to describe capillary morphology in rheumatic diseases. Rheumatology, 2016, 55, 883-890.	0.9	121
23	Association of the TNFAIP3 rs5029939 variant with systemic sclerosis in the European Caucasian population. Annals of the Rheumatic Diseases, 2010, 69, 1958-1964.	0.5	120
24	Influence of Antisynthetase Antibodies Specificities on Antisynthetase Syndrome Clinical Spectrum Time Course. Journal of Clinical Medicine, 2019, 8, 2013.	1.0	118
25	Digital ulcers predict a worse disease course in patients with systemic sclerosis. Annals of the Rheumatic Diseases, 2016, 75, 681-686.	0.5	111
26	Clinical prediction of 5-year survival in systemic sclerosis: validation of a simple prognostic model in EUSTAR centres. Annals of the Rheumatic Diseases, 2011, 70, 1788-1792.	0.5	107
27	Role of anti-cyclic citrullinated peptide antibodies in discriminating patients with rheumatoid arthritis from patients with chronic hepatitis C infection-associated polyarticular involvement. Arthritis Research, 2004, 6, R137.	2.0	104
28	Nailfold capillaroscopy in systemic sclerosis: Data from the EULAR scleroderma trials and research (EUSTAR) database. Microvascular Research, 2013, 89, 122-128.	1.1	101
29	Risk factors for a first thrombotic event in antiphospholipid antibody carriers. A multicentre, retrospective follow-up study. Annals of the Rheumatic Diseases, 2009, 68, 397-399.	0.5	98
30	Prediction of worsening of skin fibrosis in patients with diffuse cutaneous systemic sclerosis using the EUSTAR database. Annals of the Rheumatic Diseases, 2015, 74, 1124-1131.	0.5	96
31	Joint and tendon involvement predict disease progression in systemic sclerosis: a EUSTAR prospective study. Annals of the Rheumatic Diseases, 2016, 75, 103-109.	0.5	93
32	Malignancies in Patients with Anti-RNA Polymerase III Antibodies and Systemic Sclerosis: Analysis of the EULAR Scleroderma Trials and Research Cohort and Possible Recommendations for Screening. Journal of Rheumatology, 2017, 44, 639-647.	1.0	93
33	CXCL4 assembles DNA into liquid crystalline complexes to amplify TLR9-mediated interferon-Î± production in systemic sclerosis. Nature Communications, 2019, 10, 1731.	5.8	90
34	Ultrasound Elastography Assessment of Skin Involvement in Systemic Sclerosis: Lights and Shadows. Journal of Rheumatology, 2010, 37, 1688-1691.	1.0	84
35	Nailfold capillaroscopy in systemic lupus erythematosus: A systematic review and critical appraisal. Autoimmunity Reviews, 2018, 17, 344-352.	2.5	84
36	NLRP1 influences the systemic sclerosis phenotype: a new clue for the contribution of innate immunity in systemic sclerosis-related fibrosing alveolitis pathogenesis. Annals of the Rheumatic Diseases, 2011, 70, 668-674.	0.5	83

#	Article	IF	Citations
37	A gender gap in primary and secondary heart dysfunctions in systemic sclerosis: a EUSTAR prospective study. Annals of the Rheumatic Diseases, 2016, 75, 163-169.	0.5	82
38	Fast track algorithm: How to differentiate a â€œscleroderma patternâ€•from a â€œnon-scleroderma patternâ€• Autoimmunity Reviews, 2019, 18, 102394.	2.5	79
39	Progressive skin fibrosis is associated with a decline in lung function and worse survival in patients with diffuse cutaneous systemic sclerosis in the European Scleroderma Trials and Research (EUSTAR) cohort. Annals of the Rheumatic Diseases, 2019, 78, 648-656.	0.5	79
40	Transethnic meta-analysis identifies GSDMA and PRDM1 as susceptibility genes to systemic sclerosis. Annals of the Rheumatic Diseases, 2017, 76, 1150-1158.	0.5	77
41	Phenotypes Determined by Cluster Analysis and Their Survival in the Prospective European Scleroderma Trials and Research Cohort of Patients With Systemic Sclerosis. Arthritis and Rheumatology, 2019, 71, 1553-1570.	2.9	75
42	Prevalence, Correlates and Outcomes of Gastric Antral Vascular Ectasia in Systemic Sclerosis: A EUSTAR Case-control Study. Journal of Rheumatology, 2014, 41, 99-105.	1.0	73
43	Riociguat in patients with early diffuse cutaneous systemic sclerosis (RISE-SSc): randomised, double-blind, placebo-controlled multicentre trial. Annals of the Rheumatic Diseases, 2020, 79, 618-625.	0.5	71
44	Prediction of improvement in skin fibrosis in diffuse cutaneous systemic sclerosis: a EUSTAR analysis. Annals of the Rheumatic Diseases, 2016, 75, 1743-1748.	0.5	68
45	Systemic sclerosis patients with and without pulmonary arterial hypertension: a nailfold capillaroscopy study. Rheumatology, 2013, 52, 1525-1528.	0.9	67
46	Brief Report: Candidate gene study in systemic sclerosis identifies a rare and functional variant of the TNFAIP3 locus as a risk factor for polyautoimmunity. Arthritis and Rheumatism, 2012, 64, 2746-2752.	6.7	63
47	Outcomes of Barrettâ€™s oesophagus related to systemic sclerosis: a 3-year EULAR Scleroderma Trials and Research prospective follow-up study. Rheumatology, 2011, 50, 1440-1444.	0.9	62
48	SARS-CoV-2 vaccine hesitancy among patients with rheumatic and musculoskeletal diseases: a message for rheumatologists. Annals of the Rheumatic Diseases, 2021, 80, 953-954.	0.5	62
49	Anti-cyclic citrullinated peptide antibody titer predicts time to rheumatoid arthritis onset in patients with undifferentiated arthritis: results from a 2-year prospective study. Arthritis Research and Therapy, 2013, 15, R16.	1.6	60
50	Reliability of simple capillaroscopic definitions in describing capillary morphology in rheumatic diseases. Rheumatology, 2018, 57, 757-759.	0.9	60
51	Functional disability and its predictors in systemic sclerosis: a study from the DeSScipher project within the EUSTAR group. Rheumatology, 2018, 57, 441-450.	0.9	60
52	Nailfold capillaroscopy changes in systemic lupus erythematosus: correlations with disease activity and autoantibody profile. Lupus, 2005, 14, 521-525.	0.8	56
53	Gender Disparity in Susceptibility to Oxidative Stress and Apoptosis Induced by Autoantibodies Specific to RLIP76 in Vascular Cells. Antioxidants and Redox Signaling, 2011, 15, 2825-2836.	2.5	56
54	Evidence of the contribution of the X chromosome to systemic sclerosis susceptibility: Association with the functional IRAK1 196Phe/532Ser haplotype. Arthritis and Rheumatism, 2011, 63, 3979-3987.	6.7	56

#	Article	IF	Citations
55	Incidence and predictors of cutaneous manifestations during the early course of systemic sclerosis: a 10-year longitudinal study from the EUSTAR database. Annals of the Rheumatic Diseases, 2016, 75, 1285-1292.	0.5	56
56	Oxidative stress parameters in different systemic rheumatic diseases. Journal of Pharmacy and Pharmacology, 2010, 58, 951-957.	1.2	54
57	Down-regulation of natural killer cells and of g/d T cells in systemic lupus erythematosus. Does it correlate to autoimmunity and to laboratory indices of disease activity?. Lupus, 2000, 9, 333-337.	0.8	53
58	Interleukin-13 in systemic sclerosis: relationship to nailfold capillaroscopy abnormalities. Clinical Rheumatology, 2003, 22, 102-106.	1.0	50
59	Association of a KCNA5 gene polymorphism with systemic sclerosisâ€“associated pulmonary arterial hypertension in the European Caucasian population. Arthritis and Rheumatism, 2010, 62, 3093-3100.	6.7	49
60	High prevalence of capillary abnormalities in patients with diabetes and association with retinopathy. Diabetic Medicine, 2011, 28, 1039-1044.	1.2	49
61	Association of the CD226 Ser³⁰⁷ variant with systemic sclerosis: Evidence of a contribution of costimulation pathways in systemic sclerosis pathogenesis. Arthritis and Rheumatism, 2011, 63, 1097-1105.	6.7	49
62	Diagnostic value of anti-mutated citrullinated vimentin in comparison to anti-cyclic citrullinated peptide and anti-viral citrullinated peptide 2 antibodies in rheumatoid arthritis: An Italian multicentric study and review of the literature. Autoimmunity Reviews, 2012, 11, 815-820.	2.5	48
63	Prevalence, sensitivity and specificity of antibodies against carbamylated proteins in a monocentric cohort of patients with rheumatoid arthritis and other autoimmune rheumatic diseases. Arthritis Research and Therapy, 2016, 18, 276.	1.6	48
64	Autonomic dysfunction and microvascular damage in systemic sclerosis. Clinical Rheumatology, 2007, 26, 1278-1283.	1.0	44
65	The role of dietary sodium intake on the modulation of T helper 17 cells and regulatory T cells in patients with rheumatoid arthritis and systemic lupus erythematosus. PLoS ONE, 2017, 12, e0184449.	1.1	43
66	Interleukin 13 in synovial fluid and serum of patients with psoriatic arthritis. Annals of the Rheumatic Diseases, 2002, 61, 174-176.	0.5	42
67	A genetic variation located in the promoter region of the UPAR (CD87) gene is associated with the vascular complications of systemic sclerosis. Arthritis and Rheumatism, 2011, 63, 247-256.	6.7	41
68	Identification of NF-Î¹B and PLCL2 as new susceptibility genes and highlights on a potential role of IRF8 through interferon signature modulation in systemic sclerosis. Arthritis Research and Therapy, 2015, 17, 71.	1.6	41
69	Occupational therapy in ankylosing spondylitis: Short-term prospective study in patients treated with anti-TNF-alpha drugs. Joint Bone Spine, 2008, 75, 29-33.	0.8	40
70	Stabilization of Microcirculation in Patients with Early Systemic Sclerosis with Diffuse Skin Involvement following Rituximab Treatment: An Open-label Study. Journal of Rheumatology, 2016, 43, 995-996.	1.0	39
71	Predictors of disease worsening defined by progression of organ damage in diffuse systemic sclerosis: a European Scleroderma Trials and Research (EUSTAR) analysis. Annals of the Rheumatic Diseases, 2019, 78, 1242-1248.	0.5	39
72	ACE inhibitors in SSc patients display a risk factor for scleroderma renal crisisâ€”a EUSTAR analysis. Arthritis Research and Therapy, 2020, 22, 59.	1.6	38

#	Article	IF	Citations
73	Hepatitis C virus infection of salivary gland epithelial cells. Journal of Hepatology, 1997, 26, 1200-1206.	1.8	36
74	Association of circulating CXCL10 and CXCL11 with systemic sclerosis. Annals of the Rheumatic Diseases, 2018, 77, 1845-1846.	0.5	34
75	Evidence for caveolin-1 as a new susceptibility gene regulating tissue fibrosis in systemic sclerosis. Annals of the Rheumatic Diseases, 2012, 71, 1034-1041.	0.5	33
76	An international SUrvey on non-iNvaSive tecHniques to assess the mIcrocirculation in patients with RayNaudâ€™s phEnomenon (SUNSHINE survey). Rheumatology International, 2017, 37, 1879-1890.	1.5	33
77	Effect of tumor necrosis factor alpha antagonists in a patient with rheumatoid arthritis and primary biliary cirrhosis. Joint Bone Spine, 2008, 75, 87-89.	0.8	32
78	Distribution of interleukin-10 family cytokines in serum and synovial fluid of patients with inflammatory arthritis reveals different contribution to systemic and joint inflammation. Clinical and Experimental Immunology, 2015, 179, 300-308.	1.1	32
79	Long-term follow-up of low-dose methotrexate therapy in one case of idiopathic retroperitoneal fibrosis. Clinical Rheumatology, 1995, 14, 481-484.	1.0	31
80	Evaluation of Current Methods for the Measurement of Serum Anti Double-Stranded DNA Antibodies. Annals of the New York Academy of Sciences, 2007, 1109, 401-406.	1.8	28
81	Protein oxidation markers in the serum and synovial fluid of psoriatic arthritis patients. Journal of Clinical Laboratory Analysis, 2008, 22, 210-215.	0.9	28
82	Ultrasound transmission velocity of the proximal phalanxes of the non-dominant hand in the study of osteoporosis. Clinical Rheumatology, 1997, 16, 396-403.	1.0	27
83	Native/citrullinated LL37-specific T-cells help autoantibody production in Systemic Lupus Erythematosus. Scientific Reports, 2020, 10, 5851.	1.6	27
84	Brief Report: A Regulatory Variant in CCR6 Is Associated With Susceptibility to Antitopoisomeraseâ€Positive Systemic Sclerosis. Arthritis and Rheumatism, 2013, 65, 3202-3208.	6.7	26
85	Potential role for the VDR agonist elocalcitol in metabolic control: Evidences in human skeletal muscle cells. Journal of Steroid Biochemistry and Molecular Biology, 2017, 167, 169-181.	1.2	26
86	Anti-CXCL4 Antibody Reactivity Is Present in Systemic Sclerosis (SSc) and Correlates with the SSc Type I Interferon Signature. International Journal of Molecular Sciences, 2020, 21, 5102.	1.8	26
87	Sternoclavicular joint disease in psoriatic arthritis.. Annals of the Rheumatic Diseases, 1992, 51, 372-374.	0.5	25
88	Value of systolic pulmonary arterial pressure as a prognostic factor of death in the systemic sclerosis EUSTAR population. Rheumatology, 2015, 54, 1262-1269.	0.9	25
89	COVID-19 and systemic sclerosis: clinicopathological implications from Italian nationwide survey study. Lancet Rheumatology, The, 2021, 3, e166-e168.	2.2	25
90	Porphyromonas gingivalis in the tongue biofilm is associated with clinical outcome in rheumatoid arthritis patients. Clinical and Experimental Immunology, 2018, 194, 244-252.	1.1	24

#	Article	IF	Citations
91	Abnormal plasma levels of different angiogenic molecules are associated with different clinical manifestations in patients with systemic sclerosis. Clinical and Experimental Rheumatology, 2011, 29, S46-52.	0.4	24
92	Pulmonary hypertension in systemic sclerosis: prevalence, incidence and predictive factors in a large multicentric Italian cohort. Clinical and Experimental Rheumatology, 2013, 31, 31-6.	0.4	24
93	Parameters of oxidative stress status in healthy subjects: their correlations and stability after sample collection. Journal of Clinical Laboratory Analysis, 2006, 20, 139-148.	0.9	23
94	Detection of anti-IFI16 antibodies by ELISA: clinical and serological associations in systemic sclerosis. Rheumatology, 2011, 50, 674-681.	0.9	23
95	<scp>IFN</scp>â€Î² therapy modulates <scp>B</scp>â€cell and monocyte crosstalk via <scp>TLR</scp>7 in multiple sclerosis patients. European Journal of Immunology, 2013, 43, 1963-1972.	1.6	23
96	One year treatment with low dose methotrexate in rheumatoid arthritis: Effect on class specific rheumatoid factors. Clinical Rheumatology, 1993, 12, 357-360.	1.0	22
97	Class specific rheumatoid factors and antiphospholipid syndrome in systemic lupus erythematosus. Lupus, 2000, 9, 56-60.	0.8	22
98	Specific oxidative stress parameters differently correlate with nailfold capillaroscopy changes and organ involvement in systemic sclerosis. Clinical Rheumatology, 2008, 27, 225-230.	1.0	21
99	Reporting items for capillaroscopy in clinical research on musculoskeletal diseases: a systematic review and international Delphi consensus. Rheumatology, 2021, 60, 1410-1418.	0.9	20
100	Effects of rituximab in connective tissue disorders related interstitial lung disease. Clinical and Experimental Rheumatology, 2016, 34 Suppl 100, 181-185.	0.4	20
101	Phenotype of limited cutaneous systemic sclerosis patients with positive anti-topoisomerase I antibodies: data from the EUSTAR cohort. Rheumatology, 2022, 61, 4786-4796.	0.9	20
102	Case definition of psoriatic arthritis. Lancet, The, 2000, 356, 2095.	6.3	19
103	The Vitamin D Receptor Agonist BXL-01-0029 as a Potential New Pharmacological Tool for the Treatment of Inflammatory Myopathies. PLoS ONE, 2013, 8, e77745.	1.1	19
104	TGFÎ² receptor gene variants in systemic sclerosis-related pulmonary arterial hypertension: results from a multicentre EUSTAR study of European Caucasian patients. Annals of the Rheumatic Diseases, 2012, 71, 1900-1903.	0.5	18
105	What have multicentre registries across the world taught us about the disease features of systemic sclerosis?. Journal of Scleroderma and Related Disorders, 2017, 2, 169-182.	1.0	18
106	Interleukin-32 in systemic sclerosis, a potential new biomarker for pulmonary arterial hypertension. Arthritis Research and Therapy, 2020, 22, 127.	1.6	18
107	Co-occurrence of Psoriatic Arthritis with Collagenous Colitis: Clinicopathologic findings of a Case. Clinical Rheumatology, 2002, 21, 335-338.	1.0	17
108	Anti-endothelial cell antibodies in rheumatic heart disease. Clinical and Experimental Immunology, 2010, 161, 570-575.	1.1	17

#	Article	IF	Citations
109	Elevated serum levels of macrophage migration inhibitory factor and stem cell growth factor Î² in patients with idiopathic and systemic sclerosis associated pulmonary arterial hypertension. Reumatismo, 2014, 66, 270-276.	0.4	17
110	Adipokine expression in systemic sclerosis lung and gastrointestinal organ involvement. Cytokine, 2019, 117, 41-49.	1.4	17
111	Pitfalls of antinuclear antibody detection in systemic lupus erythematosus: the positive experience of a national multicentre study. Annals of the Rheumatic Diseases, 2019, 78, e50-e50.	0.5	16
112	Brief Report: Smoking in Systemic Sclerosis: A Longitudinal European Scleroderma Trials and Research Group Study. Arthritis and Rheumatology, 2018, 70, 1829-1834.	2.9	15
113	Incidence and risk factors for gangrene in patients with systemic sclerosis from the EUSTAR cohort. Rheumatology, 2020, 59, 2016-2023.	0.9	14
114	A comparison between nailfold capillaroscopy patterns in adulthood in juvenile and adult-onset systemic sclerosis: A EUSTAR exploratory study. Microvascular Research, 2015, 102, 19-24.	1.1	13
115	Revised European Scleroderma Trials and Research Group Activity Index is the best predictor of short-term severity accrual. Annals of the Rheumatic Diseases, 2019, 78, 1681-1685.	0.5	13
116	Anti-carbonic Anhydrase II Antibodies in Systemic Sclerosis: Association with Lung Involvement. Autoimmunity, 2003, 36, 85-89.	1.2	12
117	Relationship between baseline ET-1 plasma levels and outcome in patients with idiopathic pulmonary hypertension treated with bosentan. International Journal of Cardiology, 2013, 167, 220-224.	0.8	12
118	Covid-19 And Rheumatic Autoimmune Systemic Diseases: Role of Pre-Existing Lung Involvement and Ongoing Treatments. Current Pharmaceutical Design, 2021, 27, 4245-4252.	0.9	12
119	Soluble Interleukin-2 Receptor in SjoÂ¨grenâ€™s Syndrome: Relation to Main Serum Immunological and Immunohistochemical Parameters. Clinical Rheumatology, 2001, 20, 319-323.	1.0	11
120	Adhesion molecule expression in the synovial membrane of psoriatic arthritis. Annals of the Rheumatic Diseases, 2002, 61, 569-570.	0.5	11
121	Musculoskeletal ultrasound in monitoring response to apremilast in psoriatic arthritis patients: results from a longitudinal study. Clinical Rheumatology, 2019, 38, 3145-3151.	1.0	11
122	Complementary Effects of Carbamylated and Citrullinated LL37 in Autoimmunity and Inflammation in Systemic Lupus Erythematosus. International Journal of Molecular Sciences, 2021, 22, 1650.	1.8	11
123	Avascular necrosis of the femoral head in long-term follow-up of systemic sclerosis: report of two cases. Clinical Rheumatology, 1989, 8, 386-392.	1.0	10
124	Relationship of Interleukin-12 and Interleukin-13 imbalance with class-specific rheumatoid factors and anticardiolipin antibodies in systemic lupus erythematosus. Clinical Rheumatology, 2003, 22, 107-111.	1.0	10
125	Successful Immunosuppressive Treatment of Dermatomyositis: A Nailfold Capillaroscopy Survey. Journal of Rheumatology, 2010, 37, 443-445.	1.0	10
126	Nailfold capillaroscopy in SSc: innocent bystander or promising biomarker for novel severe organ involvement/progression?. Rheumatology, 2022, 61, 4384-4396.	0.9	10

#	Article	IF	Citations
127	Lupus erythematosus panniculitis: An immunohistochemical study. Clinical Rheumatology, 1994, 13, 641-644.	1.0	9
128	Methotrexate effect on anti-cyclic citrullinated peptide antibody levels in rheumatoid arthritis. Annals of the Rheumatic Diseases, 2005, 64, 1241-1242.	0.5	9
129	Anti-polymer antibodies are inversely correlated with pain and fatigue severity in patients with fibromyalgia syndrome. Autoimmunity, 2008, 41, 74-79.	1.2	9
130	Anti-aminoacyl-tRNA synthetase-related myositis and dermatomyositis: clues for differential diagnosis on muscle biopsy. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2018, 472, 477-487.	1.4	9
131	Muscle Damage in Systemic Sclerosis and CXCL10: The Potential Therapeutic Role of PDE5 Inhibition. International Journal of Molecular Sciences, 2021, 22, 2894.	1.8	9
132	Ultrasound Measurements at the Proximal Phalanges in Male Patients with Psoriatic Arthritis. Osteoporosis International, 2001, 12, 412-416.	1.3	8
133	New Autoantibody Specificities in Systemic Sclerosis and Very Early Systemic Sclerosis. Antibodies, 2021, 10, 12.	1.2	8
134	Fetal programming and systemic sclerosis. American Journal of Obstetrics and Gynecology, 2015, 213, 839.e1-839.e8.	0.7	7
135	The role of interferon-gamma release assays in predicting the emergence of active tuberculosis in the setting of biological treatment: a case report and review of the literature. Clinical Rheumatology, 2016, 35, 1383-1388.	1.0	7
136	Occupational therapy integrated with a self-administered stretching program on systemic sclerosis patients with hand involvement. Clinical and Experimental Rheumatology, 2016, 34 Suppl 100, 157-161.	0.4	7
137	Prevalence and Death Rate of COVID-19 in Autoimmune Systemic Diseases in the First Three Pandemic Waves. Relationship with Disease Subgroups and Ongoing Therapies. Current Pharmaceutical Design, 2022, 28, 2022-2028.	0.9	7
138	Nailfold capillaroscopy abnormalities are associated with the presence of anti-endothelial cell antibodies in Sjogren's syndrome. Rheumatology, 2009, 48, 704-706.	0.9	6
139	Multicentric evaluation of a second generation assay to detect antiviral citrullinated peptide antibodies: a collaborative study by the Forum Interdisciplinare per la Ricerca nelle Malattie Autoimmuni. Journal of Clinical Pathology, 2011, 64, 1139-1141.	1.0	6
140	Polymyalgia rheumatica and diverticular disease: just two distinct age-related disorders or more? Results from a case-control study. Clinical Rheumatology, 2018, 37, 2573-2577.	1.0	6
141	COVID-19 and systemic sclerosis: analysis of lifestyle changes during the SARS-CoV-2 pandemic in an Italian single-center cohort. Clinical Rheumatology, 2021, 40, 1393-1397.	1.0	6
142	An Italian Multicenter Study on Anti-NXP2 Antibodies: Clinical and Serological Associations. Clinical Reviews in Allergy and Immunology, 2022, 63, 240-250.	2.9	6
143	Safety of Multiple Vaccinations and Durability of Vaccine-Induced Antibodies in an Italian Military Cohort 5 Years after Immunization. Biomedicines, 2022, 10, 6.	1.4	6
144	Peripheral Microangiopathy Changes in Pulmonary Arterial Hypertension Related to Systemic Sclerosis: Data From a Multicenter Observational Study. Frontiers in Cardiovascular Medicine, 0, 9, .	1.1	6

#	Article	IF	Citations
145	â€œIn sickness and in healthâ€: the peculiar occurrence of polymyalgia rheumatica in married cohabiting couplesâ€”a case series and review of the literature. Clinical Rheumatology, 2016, 35, 1111-1115.	1.0	5
146	Subclinical atherosclerosis in systemic sclerosis: Different risk profiles among patients according to clinical manifestations. International Journal of Rheumatic Diseases, 2021, 24, 502-509.	0.9	5
147	From VEDOSS to established systemic sclerosis diagnosis according to ACR/EULAR 2013 classification criteria: a French-Italian capillaroscopic survey. Clinical and Experimental Rheumatology, 2018, 36 Suppl 113, 82-87.	0.4	5
148	Multiple cervical cord compressions in psoriatic arthritis. Clinical Rheumatology, 1992, 11, 51-54.	1.0	3
149	Soluble interleukin-2-receptor and interleukin-6 changes during low-dose methotrexate treatment in rheumatoid arthritis. Clinical Rheumatology, 1996, 15, 218-219.	1.0	3
150	Changes of glycosylation of serum proteins in psoriatic arthritis, studied by enzyme-linked lectin assay (ELLA), using concanavalin A. IUBMB Life, 1998, 46, 867-875.	1.5	3
151	Soluble interleukin-2 receptor and interleukin-6 levels: Evaluation during cyclosporin a and methotrexate treatment in psoriatic arthritis. Clinical Rheumatology, 1998, 17, 83-85.	1.0	3
152	Unifying abbreviations for biologics in rheumatology–does the idea hold promise?. Rheumatology, 2009, 48, 704-704.	0.9	3
153	AB0621â€…From Vedoss To Established Systemic Sclerosis Diagnosis According To The New ACR/EULAR 2013 Classification Criteria: A French-Italian Capillaroscopic Survey. Annals of the Rheumatic Diseases, 2016, 75, 1116.2-1116.	0.5	3
154	SAT0296â€…FAST TRACK ALGORITHM: HOW TO DIFFERENTIATE A SCLERODERMA PATTERN FROM A NON-SCLERODERMA PATTERN. , 2019, , .		3
155	Hyperuricemia, Gout and Idiopathic Aseptic Necrosis of Bone. Advances in Experimental Medicine and Biology, 1989, 253A, 211-214.	0.8	3
156	OP0249â€…LONG-TERM EXTENSION RESULTS OF RISE-SSC, A RANDOMIZED TRIAL OF RIOCIGUAT IN PATIENTS WITH EARLY DIFFUSE CUTANEOUS SYSTEMIC SCLEROSIS (DCSSC). Annals of the Rheumatic Diseases, 2020, 79, 156.2-157.	0.5	3
157	Antiâ€“cyclic citrullinated peptide antibody determination in the synovial fluid of patients with rheumatoid arthritis: Comment on the article by Caspi et al. Arthritis and Rheumatism, 2006, 55, 681-682.	6.7	2
158	An exploratory cross-sectional study of subclinical vascular damage in patients with polymyalgia rheumatica. Scientific Reports, 2020, 10, 11407.	1.6	2
159	Response to: â€˜Correspondence on â€˜SARS-CoV-2 vaccine hesitancy among patients with rheumatic and musculoskeletal diseases: a message for rheumatologistsâ€™â€™ by Smerilli et al. Annals of the Rheumatic Diseases, 2021, 80, e169-e169.	0.5	2
160	FRI0134â€…EFFECT OF JAK INHIBITORS ON PAIN AND QUALITY OF LIFE IN RHEUMATOID ARTHRITIS PATIENTS. Annals of the Rheumatic Diseases, 2020, 79, 649.1-649.	0.5	2
161	Nedd5, a novel autoantigen in systemic sclerosis: is it a marker of more severe disease?. Annals of the Rheumatic Diseases, 2010, 69, 314-315.	0.5	1
162	SAT0398â€…Diagnostic value of anti mutated citrullinated vimentin in comparison to anti-cyclic citrullinated peptide and anti-viral citrullinated peptide 2 antibodies in rheumatoid arthritis: A multicentric study by firma group. Annals of the Rheumatic Diseases, 2013, 71, 607.1-607.	0.5	1

#	Article	IF	Citations
163	AB0698â€...MID-Term Effects of Rituximab in Connective Tissue Disorders Related Interstitial Lung Disease (ILD). Annals of the Rheumatic Diseases, 2015, 74, 1131.2-1131.	0.5	1
164	AB0391â€...Immunogenicity of 13-Valent Conjugate Pneumococcal Vaccine in Patients with Rheumatoid Arthritis. Annals of the Rheumatic Diseases, 2015, 74, 1023.3-1024.	0.5	1
165	AB0715â€...Acute Stress: Is it a Risk Factor for the Development of Systemic Sclerosis?:. Annals of the Rheumatic Diseases, 2015, 74, 1137.2-1137.	0.5	1
166	FRI0042â€...Anti-Carbamylated Protein Antibodies in Unaffected First-Degree Relatives of Rheumatoid Arthritis Patients: Lack of Correlation with Anti-Cyclic Citrullinated Protein Antibodies and Rheumatoid Factor. Annals of the Rheumatic Diseases, 2015, 74, 434.1-434.	0.5	1
167	OP0142â€...Rituximab in systemic sclerosis : safety and efficacy data from the eustar network. , 2018, , .		1
168	POS1240â€...HYDROXYCHLOROQUINE CARDIOTOXICITY: A CASE-CONTROL STUDY COMPARING PATIENTS WITH COVID19 AND PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS. Annals of the Rheumatic Diseases, 2021, 80, 903.1-903.	0.5	1
169	POS1219â€...SARS-COV-2 VACCINE HESITANCY AMONG PATIENTS WITH RHEUMATIC AND MUSCULOSKELETAL DISEASES: A MESSAGE FOR RHEUMATOLOGISTS. Annals of the Rheumatic Diseases, 2021, 80, 893.1-893.	0.5	1
170	FRI0575â€...BIOMARKER ANALYSIS FROM THE RISE-SSC STUDY OF RIOCIGUAT IN EARLY DIFFUSE CUTANEOUS SYSTEMIC SCLEROSIS (DCSSC). Annals of the Rheumatic Diseases, 2020, 79, 890-891.	0.5	1
171	FRI0121â€...STEROID-SPARING EFFECT OF JAK INHIBITORS IN RHEUMATOID ARTHRITIS PATIENTS FOLLOWED UP IN A REAL LIFE SETTING. Annals of the Rheumatic Diseases, 2020, 79, 641.2-642.	0.5	1
172	A candidate gene study identifies a haplotype of CD2 as novel susceptibility factor for systemic sclerosis. Clinical and Experimental Rheumatology, 2016, 34 Suppl 100, 43-48.	0.4	1
173	Changes of Glycosylation of Serum Proteins in Sjogren's Syndrome: Correlation with Interleukin-6 and Soluble Interleukin-2 Receptor. IUBMB Life, 1999, 48, 385-390.	1.5	0
174	Changes of Glycosylation of Serum Proteins in Sjogren's Syndrome: Correlation with Interleukin-6 and Soluble Interleukin-2 Receptor. IUBMB Life, 1999, 48, 385-390.	1.5	0
175	Case definition of psoriatic arthritis. Lancet, The, 2000, 356, 2095-2096.	6.3	0
176	Potential adipokine involvement in systemic sclerosis. Annals of the Rheumatic Diseases, 2010, 69, A25-A25.	0.5	0
177	Evidence forCaveolin-1 (CAV1)as a new susceptibility gene regulating tissue fibrosis in systemic sclerosis. Annals of the Rheumatic Diseases, 2012, 71, A52.2-A53.	0.5	0
178	OP0225â€...Do worsening scleroderma capillaroscopic patterns predict novel future severe organ involvement in systemic sclerosis? A pilot study. Annals of the Rheumatic Diseases, 2013, 71, 131.3-132.	0.5	0
179	FRI0454â€...Hand function in systemic sclerosis: Effect of occupational therapy on the health status and quality of life. Annals of the Rheumatic Diseases, 2013, 71, 468.1-468.	0.5	0
180	AB0624â€...High Levels of Proinflammatory Biomarkers in Patients with Idiopathic Inflammatory Myopathies. Annals of the Rheumatic Diseases, 2014, 73, 1012.1-1012.	0.5	0

#	Article	IF	Citations
181	SAT0432â€…Performance of the New EULAR/ACR 2013 Classification Criteria for Systemic Sclerosis in the Clinical Practice: A Single Center Experience. Annals of the Rheumatic Diseases, 2015, 74, 816.1-816.	0.5	0
182	OP0055â€…Anti-RNA Polymerase III Antibodies in Patients with Systemic Sclerosis: A Eustar Multicenter Collaborative Study. Annals of the Rheumatic Diseases, 2015, 74, 88.1-88.	0.5	0
183	AB1086â€…An Eular Study Group Pilot Study on Reliability of â€œSimpleâ€•Capillaroscopic Definitions to Describe Capillary Morphology in Rheumatic Diseases. Annals of the Rheumatic Diseases, 2015, 74, 1263.3-1264.	0.5	0
184	AB0203â€…Possible Role of Fractalkine/CX3CL1 (FKN) in the Microvascular Damage of Systemic Sclerosis (SSC). Annals of the Rheumatic Diseases, 2015, 74, 958.3-959.	0.5	0
185	AB0601â€…Significant Cardiological Changes in Systemic Sclerosis: An Electrocardiographic and Echocardiographic Evaluation: Table 1.. Annals of the Rheumatic Diseases, 2016, 75, 1110.1-1110.	0.5	0
186	OP0031â€…Risk Factors for Malignancies Synchronous To The Onset of Systemic Sclerosis in Patients Positive for Anti- RNA Polymerase III Antibodies: A Eustar Multicentre Study. Annals of the Rheumatic Diseases, 2016, 75, 64.2-64.	0.5	0
187	SAT0196â€…Impress 2 (International Multicentric Prospective Study on Pregnancy in Systemic Sclerosis). Prospective, Case-Control Study of Pregnancy in Systemic Sclerosis. Annals of the Rheumatic Diseases, 2016, 75, 739.1-739.	0.5	0
188	THU0006â€…Trans-ethnic meta-analysis of genome-wide association studies identifies GSDMA and PRDM1 as susceptibility genes to systemic sclerosis. , 2017, , .		0
189	THU0252â€…Nailfold capillaroscopy in systemic lupus erythematosus: a systematic review and critical appraisal. , 2017, , .		0
190	FRI0045â€…Oral microbiome profile in rheumatoid arthritis patients: association between tongue biofilm porphyromonas gingivalis amount and disease activity. , 2017, , .		0
191	AB0029â€…Anti inflammatory effect of pde5 inhibition: scope for a new potential indication in ssc associated myositis. , 2017, , .		0
192	AB0030â€…The effect of sildenafil and iloprost on cxcl10 level in systemic sclerosis: in vivo and in vitro comparison. , 2017, , .		0
193	THU0334â€…Evaluation of subclinical vascular damage in patients with polymyalgia rheumatica: a cross-sectional study using an integrated, non-invasive approach of color doppler ultrasound and cardio-ankle vascular index (CAVI) measurement of arterial stiffness. , 2017, , .		0
194	SAT0347â€…Disease modifying effect of iloprost in patients with systemic sclerosis and possible role of CXCL4 chemokine. , 2017, , .		0
195	AB0220â€…ALPHA- SMOOTH MUSCLE ACTIN EXPRESSION ON ENDOTHELIAL PROGENITORS CELLS OF SYSTEMIC SCLEROSIS PATIENTS: POSSIBLE ROLE IN THE ENDOTHELIAL-TO-MESENCHIMAL TRANSITION PROCESS. , 2019, , .		0
196	THU0020â€…COMPARATIVE STUDY OF THE PHOSPHODIESTERASE TYPE 5 INHIBITOR SILDENAFIL AND THE PROSTACYCLIN ANALOGUE ILOPROST ON IP10 MODULATION IN SYSTEMIC SCLEROSIS. , 2019, , .		0
197	AB0688â€…NEOPLASTIC RISK IN SYSTEMIC SCLEROSIS: A MONOCENTRIC STUDY. , 2019, , .		0
198	FRI0650â€…A NAILFOLD CAPILLAROSCOPY STUDY IN A COHORT OF PATIENTS WITH ANTI-PHOSPHOLIPID ANTIBODIES. , 2019, , .		0

#	Article	IF	Citations
199	AB0389â€…BIOSIMILAR ETANERCEPT VERSUS ORIGINATOR: RESULTS FROM A LONGITUDINAL PROSPECTIVE MONOCENTRIC STUDY. , 2019, , .		0
200	Helicobacter pylori and Upper Endoscopy in Systemic Sclerosis. Journal of Clinical Rheumatology, 2021, 27, 40-41.	0.5	0
201	OP0246â€…PREDICTIVE VALUE OF LABORATORY AND INSTRUMENTAL FINDINGS IN THE VERY EARLY DIAGNOSIS OF SYSTEMIC SCLEROSIS. ROLE FOR CXCL4 CHEMOKINE. Annals of the Rheumatic Diseases, 2021, 80, 150.2-151.	0.5	0
202	POS1185â€…IMPACT OF LOCKDOWN DURING COVID-19 PANDEMIC ON THE ONSET OF POST-TRAUMATIC STRESS DISORDER (PTSD) IN SYSTEMIC SCLEROSIS PATIENTS: A CASE-CONTROL STUDY. Annals of the Rheumatic Diseases, 2021, 80, 873.2-874.	0.5	0
203	POS0321â€…USE OF HYDROXYCHLOROQUINE AND SYSTEMIC SCLEROSIS: RESULTS FROM A PROSPECTIVE OBSERVATIONAL STUDY ON THE EUSTAR COHORT. Annals of the Rheumatic Diseases, 2021, 80, 387.3-388.	0.5	0
204	POS0317â€…THE PERFORMANCE OF DIFFUSING CAPACITY FOR MONOXIDE CARBON (DLCO) AND FORCED VITAL CAPACITY (FVC) IN PREDICTING THE ONSET OF SYSTEMIC SCLEROSIS (SSc)-INTERSTITIAL LUNG DISEASE (ILD) IN THE EUROPEAN SCLERODERMA TRIALS AND RESEARCH (EUSTAR) DATABASE. Annals of the Rheumatic Diseases, 2021, 80, 385-386.	0.5	0
205	POS0433â€…CAN INTERLEUKIN 33 (IL-33) BE CONSIDERED A VALUABLE BIOMARKER IN THE EARLY STAGES OF SYSTEMIC SCLEROSIS? ANALYSIS OF A MONOCENTRIC COHORT. Annals of the Rheumatic Diseases, 2021, 80, 445.2-445.	0.5	0
206	POS0861â€…EFFECTIVENESS AND SAFETY OF TOCILIZUMAB IN PATIENTS WITH SYSTEMIC SCLEROSIS: A PROPENSITY SCORE CONTROL MATCHED OBSERVATIONAL STUDY OF THE EUSTAR COHORT. Annals of the Rheumatic Diseases, 2021, 80, 685-686.	0.5	0
207	AB0234â€…SURVIVAL OF ABATACEPT IN RHEUMATOID ARTHRITIS PATIENTS: A REAL-LIFE STUDY. Annals of the Rheumatic Diseases, 2021, 80, 1143.1-1143.	0.5	0
208	POS1246â€…COVID-19 IN ITALIAN PATIENTS WITH RHEUMATIC AUTOIMMUNE SYSTEMIC DISEASES: RESULTS OF A NATIONWIDE SURVEY STUDY. Annals of the Rheumatic Diseases, 2021, 80, 906-907.	0.5	0
209	FRI0242â€…Watermelon stomach in systemic sclerosis: A EUSTAR case-control study. Annals of the Rheumatic Diseases, 2013, 71, 396.1-396.	0.5	0
210	OP0091â€…Cxcl10/cxcl11 serum measurement as potential predictor of systemic sclerosis. , 2018, , .		0
211	FRI0239â€…ANTI-NXP2 ANTIBODIES: CLINICAL AND SEROLOGICAL ASSOCIATIONS IN A MULTICENTRIC ITALIAN STUDY. Annals of the Rheumatic Diseases, 2020, 79, 703.1-704.	0.5	0
212	SAT0555â€…MUSCULOSKELETAL ULTRASOUND IN MONITORING RESPONSE TO JAKi IN RHEUMATOID ARTHRITIS PATIENTS: RESULTS FROM A LONGITUDINAL STUDY. Annals of the Rheumatic Diseases, 2020, 79, 1235-1236.	0.5	0
213	SAT0296â€…SERUM LEPTIN LEVELS IN SYSTEMIC SCLEROSIS PATIENTS WITH ELECTROCARDIOGRAPHIC ABNORMALITIES. Annals of the Rheumatic Diseases, 2020, 79, 1093.1-1093.	0.5	0
214	AB0170â€…PHENOTYPIC CHARACTERIZATION OF ENDOTHELIAL PROGENITORS CELLS OF SYSTEMIC SCLEROSIS (SSC) PATIENTS: ROLE IN ENDOTHELIAL-TO-MESENCHIMAL TRANSITION PROCESS. Annals of the Rheumatic Diseases, 2020, 79, 1385.1-1385.	0.5	0
215	Psychological Fragility in an Italian Cohort of Systemic Sclerosis Patients During COVID-19 Pandemic Category: Short Communication. Open Access Rheumatology: Research and Reviews, 0, Volume 14, 133-139.	0.8	0